Strides Pharma Reports Strong Financial Performance in Q4 2023

Strides Pharma Science, a midcap pharmaceutical company, has recently announced its financial results for the quarter ended December 2023. The company has shown a very positive performance in this quarter, with its score improving from 9 to 23 in the last 3 months.

One of the key highlights of the financials is the significant growth in Profit After Tax (PAT) which has increased by 140.9% year on year (YoY) to reach Rs 49.67 crore. This trend is expected to continue in the near term. Additionally, Strides Pharma has also shown a strong ability to manage its interest payments, with the Operating Profit to Interest ratio being the highest in the last five quarters at 2.44 times.

Another positive aspect of the financials is the company's inventory turnover ratio, which has been consistently growing each half year in the last five periods and is currently at its highest at 3.32 times. This indicates that Strides Pharma has been able to sell its inventory at a faster rate.

In terms of sales, the company has achieved its highest quarterly net sales of Rs 1,037.67 crore in the last five quarters, with a positive trend expected in the near term. The Operating Profit (PBDIT) has also reached its highest at Rs 193.81 crore in the last five quarters, with a positive trend in the near term.

Furthermore, Strides Pharma has shown an improvement in its efficiency with the highest Operating Profit Margin of 18.68% in the last five quarters. This indicates that the company has been able to generate higher profits from its operations.

Overall, the company's financial performance in the quarter ended December 2023 has been very positive, with a strong growth in key financial indicators such as PAT, sales, and operating profit. This is reflected in the stock call given by MarketsMOJO, which is 'Hold'.